LifeSci Advisors Initiates Coverage of La Jolla Pharmaceutical Company
April 25 2012 - 10:30AM
Marketwired
LifeSci Advisors, LLC, a leading provider of investment research
and investor relations services in the life sciences sector, today
announced that it has initiated coverage of La Jolla Pharmaceutical
Company, Inc. (OTCQB: LJPC) (PINKSHEETS: LJPC), a leading
biotechnology company dedicated to developing galectin antagonists
for the treatment of major life threatening diseases including
chronic organ failure and cancer. The prospects of the Company's
lead asset, GCS-100, are highlighted in the initiation report with
a particular focus on the treatment of renal insufficiency and
related fibrotic disorders.
"There has been a recent explosion in scientific evidence
establishing galectin-3 as a causative or culprit biomarker in
organ fibrosis, which leads to organ failure. Specifically, it is
now known that galectin-3 plays a key role in the progression of
renal, hepatic and cardiac fibrosis," said Andrew I. McDonald,
Ph.D., Managing Director at LifeSci Advisors. "As an agent capable
of selectively inhibiting galectin-3, GCS-100 could provide a
significant therapeutic benefit for patients suffering from all of
these diseases."
In January 2012, La Jolla Pharmaceutical Company acquired
worldwide development and commercialization rights to GCS-100, a
potent and selective inhibitor of galectin-3 and gained the
seasoned management team from Solana Therapeutics.
In an Initiation Report by LifeSci Advisors, we explain the
scientific basis and prospects for La Jolla Pharmaceutical
Company's GCS-100. GCS-100 has been administered to over 140
patients in nine Phase 1 and Phase 2 clinical trials and has been
shown to be well tolerated at therapeutically relevant doses. It
has shown promising activity against a variety of cancers,
including chronic lymphocytic leukemia (CLL), multiple myeloma (MM)
and renal cell carcinoma (RCC). While GCS-100 still represents a
potentially new and important treatment for cancer, La Jolla
Pharmaceutical Company intends to explore several other non-cancer
development opportunities, including those opportunities related to
fibrosis organ failure, which have recently come to light.
Specifically, LJPC intends to first evaluate weekly doses of
GSC-100 in patients with cancer who have renal insufficiency.
Dr. McDonald's full Initiation Report is available to download
at no cost at the LifeSci Advisors website,
www.lifesciadvisors.com. In addition to this Initiation Report,
LifeSci Advisors will also provide ongoing coverage and event-based
research updates on the Company as developments occur.
The LifeSci Advisors research team is led by Dr. Andrew I.
McDonald, an industry veteran with more than 15 years of healthcare
industry experience. Prior to co-founding LSA, Dr. McDonald was the
Senior Biotechnology Analyst at Great Point Partners, a leading
health care investment firm with over $500 million under
management. Before Great Point, he was Co-Head of Healthcare
Research and Lead Biotechnology Analyst at ThinkEquity Partners, a
boutique investment banking firm focused on growth companies. Dr.
McDonald holds a Ph.D. in organic chemistry from the University of
California, Irvine, and, earlier in his career, worked as a
medicinal chemist at both Pfizer and Cytokinetics.
About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and
communications consultancy dedicated to the life sciences industry.
The firm provides strategic counsel, customized marketing
communications, comprehensive research reports and investor
relations services to companies that specialize in the discovery,
development and commercialization of drugs, drug delivery systems,
medical devices and diagnostics. To learn more about LSA, visit the
company's website, www.lifesciadvisors.com.
Important Disclosures:
The research report described in this press release is not
intended as an offering, recommendation, or a solicitation of an
offer to buy or sell securities. The securities discussed in LSA
research reports may be unsuitable for some investors depending on
their specific investment objectives, financial status, risk
profile, or particular needs. Investors should consider LSA reports
as only a single factor in making their investment decisions and
should not rely solely on these reports in evaluating whether or
not to buy or sell the securities of the subject company. LifeSci
Advisors has been compensated by the company that is the subject of
the report described and future research reports, investor
relations services, and general consulting services. Please read
each report's full disclosures and analyst background on the LSA
website, www.lifesciadvisors.com, before investing. LifeSci
Advisors is not a registered investment adviser or
broker-dealer.
Forward-looking statements:
This press release contains forward-looking statements subject
to risks and uncertainties that could cause actual results to
differ materially from those projected. These forward-looking
statements represent LSA's judgment as of the date of this release.
LifeSci Advisors disclaims, however, any intent or obligation to
update these forward-looking statements.
Media Contact: Michael Rice Phone: (646) 597-6979 Email:
mrice@lifesciadvisors.com
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From May 2024 to Jun 2024
La Jolla Pharmaceutical (NASDAQ:LJPC)
Historical Stock Chart
From Jun 2023 to Jun 2024